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344Successful Hematopoietic Stem Cell Transplantation in
2 Children with X-Linked Chronic Granulomatous
Disease from Their Unaffected HLA-Identical Siblings
Selected Using Preimplantation Genetic Diagnosis
Combined with HLA Typing
Evgenios Goussetis,1 Christopher P. Konialis,2 Ioulia Peristeri,1 Vasiliki Kitra,1
Maria Dimopoulou,1 Theoni Petropoulou,3 George Vessalas,1 Andreas Papassavas,4
Marianna Tzanoudaki,5 Georgia Kokkali,6 Eftychia Petrakou,1 Antonia Spiropoulos,1
Constantinos G. Pangalos,2 Konstantinos Pantos,6 Stelios Graphakos1We report 2 children with X-linked chronic granulomatous disease (X-CGD) who underwent hematopoietic
stem cell transplantation (HSCT) using grafts from their siblings selected before implantation to be both un-
affected and HLA-matched donors. Preimplantation genetic diagnosis (PGD) along with HLA-typing were
performed on preimplantation embryos by single-cell multiplex polymerase chain reaction using informative
short tandem repeat markers in the HLA locus together with the gene region containing the mutations. Two
singleton pregnancies resulted from the intrauterine transfer of selected embryos; these developed to term,
producing 1 healthy female and 1 X-CGD carrier female, which are HLA-identical siblings to the 2 affected
children. Combined grafts of umbilical cord blood (UCB) and bone marrow (BM) stem cells were adminis-
tered to the recipients after myeloablative (MA) conditioning at the ages of 4.5 years and 4 years, respectively.
Both patients are well, with complete donor hematopoietic and immunologic reconstitution, at 18 and 13
months posttransplantation, respectively. This report demonstrates that HSCT with HLA-matched sibling
donors created by PGD/HLA typing of in vitro fertilized embryos is a realistic therapeutic option and should
be presented as such to families with children who require a non-urgent HSCT but lack an HLA-genoidentical
donor.
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X-linked chronic granulomatous disease
(X-CGD) is an inherited defect in phagocyte nicotin-
amide adenine dinucleotide phosphate oxidase result-
ing from a deficiency of gp91phox component. At the
molecular level, X-CGD is caused by mutations
affecting the CYBB gene on chromosome Xp21.1
[1,2]. As a result of impaired phagocytic ability,
affected persons suffer from severe recurrent infec-
tions, both bacterial and fungal, resulting in the
formation of infiltrating granulomatous lesions.
Despite prophylactic therapy, long-term survival
remains poor; only 50% of patients are alive at the
age of 30 years [3,4]. Allogeneic hematopoietic stem
cell transplantation (HSCT) using an HLA-matched
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X-CGD in 80% to 90% of cases [5,6]. A healthy
MSD is not available in the vast majority of the cases,
however. For such patients, a matched unrelated
donor (MUD) is a suitable option, but at the cost
of increased teatment-related morbidity and mortal-
ity (TRM) [5,7]. Preimplantation genetic diagnosis
(PGD) for single-gene diseases was developed to
help families desiring a new pregnancy to select unaf-
fected embryos in vitro, thereby avoiding the need for
pregnancy termination. Recently, this strategy has
been combined with HLA typing with the aim of
selecting suitable histocompatible embryos as poten-
tial stem cell donors for affected siblings [8-10].
There is limited experience with this methodology
and even less with its completed clinical application,
however.METHODS
Patient Characteristics
Patient 1
In this 4.5-year-old boy with an established diag-
nosis of X-CGD since infancy, diagnosis was con-
firmed by respiratory burst screening tests and by
DNA CYBB gene sequencing (R73X C / T muta-
tion). Despite both antimicrobial and interferon-g
prophylaxis, the patient had recurrent infections
from the age of 4 months onward, and granulomatous
colitis was diagnosed at the age of 1.7 years.
Patient 2
This 4-year-old boy was diagnosed with X-CGD
at age 6 months by both functional and molecular tests
(R157X C / T mutation). Before presenting for
HSCT, he had experienced multiple cervical abscesses
despite receiving antibiotic prophylaxis.
Donor Selection
Neither patient had an HLA-genoidentical sibling
donor. The patients’ parents came to the Diagnostic
Genetic Centre in Athens on their own initiative for
genetic consultation. After detailed genetic counsel-
ing, the couples came to the Centre for Human Repro-
duction, Genesis Athens Hospital for complete
counseling regarding in vitro fertilization (IVF) and
embryo biopsy procedures. The clinical protocol was
approved by the center’s Institutional Research and
Ethics Committee for the IVF treatment, embryo bi-
opsy, and PGD procedures required for the transfer
of unaffected and HLA-identical embryos to the
mother’s uterus. Written informed consent concern-
ing the PGD/HLA typing procedure, as well as the
cryopreservation of nontransferred embryos for future
use, in accordance with the Helsinki Declaration, wasobtained from both couples. A single cycle of IVF was
initiated for each couple, and standard hormonal stim-
ulation and culture techniques were used to generate
embryos for PGD and HLA genotyping [11,12]. All
fertilized embryos were cultured and biopsied by laser
on day 3 in the first couple and on day 5 for the second
couple [13]. Embryo genotyping was performed using
a nested multiplex polymerase chain reaction (PCR)
approach, involving first- and second-round amplifica-
tion of the informative polymorphic short tandem
repeat (STR) markers previously selected by extensive
HLA genotyping and haplotype analysis of the family
members. Detection of the disease mutation was per-
formed by minisequencing [14]. Embryos identified
to be HLA-identical to the patients and unaffected
by X-CGD (homozygous wild-type allele or heterozy-
gous mutation) were transferred 6 days after fertiliza-
tion to the uterus of the respective mothers. The 2
singleton full-term pregnancies resulted in the birth
of 1 healthy and 1 X-CGD carrier female siblings.
Confirmatory genetic testing was performed using
chorionic villus sampling in the first trimester for
CGDmutations andHLA typing. To rule out the pos-
sibility of extreme inactivation of the X chromosome in
the case of the heterozygotic sibling donor carrying the
nonmutated CYBB, postnatal neutrophil superoxide
production was measured.HSCT
Umbilical cord blood (UCB) was collected, frozen,
and stored in liquid nitrogen as described previously
[15]. Given the limited experience with UCB trans-
plantation (UCBT) in patients with X-CGD, we de-
cided to combine UCB and bone marrow (BM) HSC
from the same donors, to ensure stable long-term en-
graftment. Therefore, after parental written consent
was provided, when the 2 sibling donors reached age
16 months, reduced-volume BM was harvested. Both
patients were conditioned with busulfan (Bu; 16 mg/
kg i.v) and cyclophosphamide (Cy; 200 mg/kg i.v.).
Graft-versus-host disease (GVHD) prophylaxis com-
prised cyclosporine A and a short course of methotrex-
ate (MTX). Time to white blood cell engraftment was
defined as the first of 3 consecutive days with a neutro-
phil count. 0.5 109/L, and platelet engraftment was
defined as the first of 3 consecutive days on which
a platelet count. 20  109/L was maintained without
transfusion. To assess engraftment and the degree of
chimersm, patients were monitored at different time
points, using a PCR assay to identify genetic polymor-
phism of STRs. Superoxide production by neutrophils
was measured by the dihydrorhodamine (DHR) test.
Expression of gp91phox on neutrophils was measured
using the 7D5 monoclonal antibody (mAb) and flow
cytometry.
Table 1. Summary of the PGD/HLA typing results
Family
IVF
Cycle
Embryos
Formed
HLA-Matched,
CGD-Unaffected
Embryos
Embryos
Transferred Pregnancies
1 1 37 6* 2 1
2 1 11 2† 2 1
PGD indicates preimplantation genetic disease; CGD, chronic granuloma-
tous disease. Biopsies were performed at the cleavage stage (day 3 after
fertilization) for family 1 and at the blastocyst stage (day5 after fertilization)
for family 2.
*Four embryos were homozygous for the wild-type allele.
†Both embryos were carriers for the CGD mutation.
Table 2. Characteristics of patients, donors, and grafts, and
transplantation outcome
Patient 1 Patient 2
Age, years 4.5 4
Sex Male Male
Donor sex Female Female
X-CGD carrier donor No Yes
UCB volume collected, mL 112 143
UCB nucleated cells/kg 1.4  107 10  107
UCB CD34+ cells/kg 0.35  105 2.8  105
BM volume collected, mL 174 100
BM nucelated cells/kg 3.2  108 3  108
BM CD34+ cells/kg 13.6  106 7.5  106
Neutrophil engraftment Day +20 Day +18
Platelet engraftment Day +19 Day +17
GVHD No No
Chimerism Full donor Full donor
CGD indicates chronic granulomatous disease; UCB, umbilical cord
blood; BM, bone marrow; GVHD, graft-versus-host disease.
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PGD/HLATyping of Embryos
Each family was subjected to a single clinical IVF
cycle. A total of 48 embryos were tested for the 2 cou-
ples. Eight of these embryos were diagnosed as unaf-
fected and HLA-matched, and 2 embryos from each
cycle were transferred, resulting in 2 singleton preg-
nancies and 2 newborns, 1 healthy and 1 X-CGD car-
rier. All X-CGD–unaffected embryos not transferred
were cryopreserved for eventual future use. Table 1
summarizes the PGD/HLA typing results.
Graft Characteristics
The numbers of UCB-nucleated and CD341 cells
collected from the first donor (1.4  107/kg and 3.5 
104/kg, respectively) were deemed insufficient to se-
cure long-term engraftment. Therefore, we decided
to increase the number of hematopoietic progenitors
by harvesting a reduced BM volume from the same do-
nor. In the case of second donor, and despite an ade-
quate number of cells in the UCB unit, we decided
to harvest a small volume (100 mL) of BM to further
enrich the number of hematopoietic progenitors. Co-
infusion of BM cells in the second case was chosen be-
cause of the extremely limited experience with
matched related UCBT in X-CGD and the high risk
of graft failure reported in small series of children un-
dergoing unrelated UCBT [16]. In both cases, BMwas
harvested when the donors reached the age of 16
months. Details on the number of nucleated and
progenitor cells of the grafts are given in Table 2.
Transplantation Outcome
Both patients engrafted quickly after receiving
a combined graft of UCB and BM cells. Neutrophil
engraftment was achieved on day 120 in patient 1
and on day 118 in patient 2, and platelet engraftment
occurred ondays119 and117, respectively.Complete
donor-derived hematopoietic chimerism was repeat-
edly detected after day 160 posttransplantation by
studying STRs. Neither patient developed acute or
chronic graft-versus-host disease (aGVHD, cGVHD).
Cyclosporine (CsA) and replacement i.v. immunoglob-
ulin were stopped at 6 months posttransplantation.
Patient 1 had normal stools since day 130 posttrans-
plantation, indicating resolution of colitis. In patient
1, both DHR and gp91phox expression were restored
to normal on 100% of the neutrophils posttransplanta-
tion, whereas in patient 2, only 50% of neutrophils
exhibited normal DHR and gp91phox expression post-
transplantation. Repeated testing revealed similar
results at various time intervals posttransplantation
(Figure 1). At their last follow-up visit, both patients
were in excellent clinical condition, demonstrating
normal hematopoietic and immunologic reconstitu-tion at 18 and 13 months posttransplantation, respec-
tively.DISCUSSION
The practice of conceiving an additional child with
the intentionof using it as anHSCdonor for an affected
sibling has been done for many years [17]. In the early
years, parents planned to have another child by natural
conception and hoped for an HLA-matching sibling.
More recently, Verlinsky et al. [18] reported HLA
typing combined with PGD in a case of Fanconi
anemia. Although only 3/16 embryos for X-linked
recessive inheritance will be both disease-free and
HLA-identical, the likelihood of conceiving a matched
donor using PGD/HLA typing is much greater than
that with a spontaneous conception. Only a limited
number of PGD centers offering HLA typing on
human preimplantation embryos exist worldwide, lim-
iting experiencewith the combination of IVF andPGD
to achieve pregnancy and birth of a healthy HLA-
compatible sibling. Published data fromdifferent series
worldwide have reported 64 children born after PGD/
HLA testing; the pregnancy rate per embryo transfer
was 34% on average, varying depending on the IVF
center and age of themother [10,19,20]. All 64 children
were healthy and HLA-identical to their affected
Figure 1. Oxidative burst activity of neutrophils, expression of gp91phox, and hematopoietic chimerism. Both H2O2-producing granulocytes after phor-
bol myristate acetate stimulation by fluorescent activated cell sorting analysis (DHR test) and expression of gp91phox posttransplantation were corrected
after transplantation. DHR before transplantation (A and B) showed neutrophils with no oxidative burst activity, whereas both DHR (C and D) and
gp91phox expression (E and F) at 18 and 13 months posttransplantation, respectively, for patients 1 and 2 showed 100% corrected neutrophils for patient
1 and a 50% mosaicism for patient 2. Hematopoietic chimerism analysis by STR-PCR at 18 and 13 months posttransplantation, respectively, for patients 1
and 2 revealed 100% donor genotype (G and H). Lane 1, donor; lane 2, recipient; lane 3, recipient posttransplantaton.
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ing to the cure of affected siblings have been reported
[19,21,22]. Although no mistakes on HLA typing
have been reported so far, the possibility of misdiagno-
sis of either HLA typing or PGD resulting from tech-
nical and human errors cannot be excluded [19,23].
Therefore, it must bemade clear to the family that pre-
natal diagnosis is an absolute requirement to rule out an
affected pregnancy. In addition, the use of this method
raises a number of practical and ethical issues, such as
the creation of human beings solely for instrumental
use, most of which can be addressed by careful genetic
and psychological counseling of the parents [24-26].
Other significant open issues remain, including the
fate of unused healthy HLA-nonidentical embryos
that greatly exceed the number created to address infer-
tility. The law on medically assisted reproduction
should provide regulations regarding the use of
PGD/HLA typing and determine the fate of unused
healthy embryos. In some countries, regulations permit
the transfer of selected embryos based on HLA typing
in combination with PGD, whereas in others this is not
allowed. Clearly, further research is required to eluci-
date the clinical, social, psychological, and economic
issues that might be relevant to the application of this
technology.Although infusion of autologous HSC genetically
modified to express gp91phox has been associated with
some transitory benefits in a few patients, the safety
and efficacy of gene therapy inX-CGDremainofmajor
concern [27,28]. Currently, allogeneic HSCT from an
HLA-matched donor is the only therapeutic modality
with curative potential for patients with X-CGD. Allo-
geneic HSCT is best performed at an early age in chil-
dren with recurrent serious infections despite
antimicrobial prophylaxis [6,29]. A recent study of
the efficacy of allogeneic HSCT in 20 patients with
X-CGD found that the type of donor (MSD or
MUD) had no effect on transplantation outcome
[30]. It is obvious, however, that the efficacy and safety
of MUD-HSCT should be examined in larger cohorts
of patients.Moreover, aMUDis available for only 60%
to 70% of the patients in need of a donor, possibly even
lower in patients of ethnic minorities [31]. Experience
with either related or unrelated UCB as the source of
HSC for patients with X-CGD is very limited, and
only a few cases have been reported so far [32].
Following the recently published first case report
of successful HSCT of an X-linked-CGD patient us-
ing preimplantation female sex typing and HLA-
typing [33], we describe 2 additional patients who
underwent successful transplantation from a matched
348 Biol Blood Marrow Transplant 16:344-349, 2010E. Goussetis et al.healthy sibling preselected by combined PGD and
HLA typing.We chose to use PGD rather than female
gender selection to detect the disease-specific muta-
tion, to preclude the rejection of unaffected male em-
bryos that cannot be differentiated from those affected
when using fluorescein in situ hybridization (FISH) for
female sex typing.
PGD/HLA typing technology should be consid-
ered and discussed with parents in cases where no suit-
able MSD is available and transplantation using an
unrelated donor either carries significantly higher risks
than the use of a sibling donor or is not possible
because of the unavailability of a suitable MUD. The
foregoing methodology can be applied in patients
requiring nonurgent HSCT, such as patients with
a genetic disease or children who may require trans-
plantation in the future because of progression of an
underlying disease, such as acute lymphoblastic leuke-
mia ALL) in first complete remission (CR1) (20). In
addition, the parents of the affected child still must
be in reproductive age. Before making any decision,
parents should be informed about the efficacy and
safety of all alternative options, such as allogeneic
HSCT using anMUD or an unrelated UCB unit. Par-
ents also should be informed about the possibility of
using BM or reduced-volume BM plus UCB, as in
our patients reported here, especially when insufficient
UCB cells are available. A high cell dose (. 3.7 107/
kg) is considered crucial to sustain engraftment in pa-
tients with nonmalignant diseases undergoing MRD-
UCBT [34]. Although in patient 2, the UCB nucleated
cells would have been sufficient to secure engraftment
without the addition of BM cells, we chose to combine
UCB and BM to increase the cell dose because of the
limited and not encouraging experience with UCBT
in patients with X-CGD patients [32]. However, BM
harvest, especially from a pediatric donor, is an inva-
sive procedure and should be chosen only after UCB
collection or transplantation fails. In such cases, we
recommend delaying transplantation until the donor
is between the ages of 12-24 months. Within this age
range, depending on the recipient’s weight, a reduced
BM volume not exceeding 15 mL/kg donor weight
should suffice. Alternative strategies pursued to obtain
a high rate of engraftment in the presence of insuffi-
cient UCB include coinfusion of third-party mesen-
chymal stem cells [35] or mobilized CD341 cells
[36]. However, the available data are insufficient to of-
fer such a strategy as an alternative to BM cells
obtained from the same donor to increase the engraft-
ment potential of the UCB graft.
In conclusion, transplant physicians should be
aware of the feasibility and efficacy of the PGD/HLA
typing method as well as the indications of its use.
Regardless of the final decision, an immediate search
for a suitable unrelated donor at the time of establishing
the indication for HSCT should never be omitted.ACKNOWLEDGMENTS
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